Compare Abeona Therapeutics Inc (ABEO) vs Garmin Ltd. (GRMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Garmin Ltd. — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Garmin Ltd. trades at $244.1 (market cap $47.96B). The key difference: Garmin Ltd. is far larger — about 128.5× Abeona Therapeutics Inc's market cap, and Garmin Ltd. pays a 1.69% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GRMN | |
|---|---|---|
Market Cap | $373.32M | $47.96B |
Sector | Health | Technology |
52-Week High | $7.23 | $267.52 |
52-Week Low | $4.17 | $187.10 |
Enterprise Value | $228.22M | $45.43B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Garmin (GRMN) trades at $248.68, up 3.63% today, reflecting strong momentum near its recent highs. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 23.26% net income margin and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent product launches like LiveScope 2 and positive earnings beats in Q4 2025 and Q1 2026 underscore operational strength.
The outlook remains favorable with a consensus price target of $282.67, though risks include competitive pressures and market volatility. Investment appeal centers on sustained profitability and innovation, but investors should weigh high valuation multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
